Kalshi pilots clinical trial event contracts with AppliedXL partnership
Kalshi is piloting event contracts on late-stage clinical trial outcomes through a partnership with event detection platform AppliedXL. The pilot launches 13 new biotech contracts, expanding the regulated prediction market's offerings beyond political and economic events into healthcare outcomes. Traders can now take positions on drug trial results and FDA regulatory decisions. The pilot represents a measured entry into biotech, Kalshi's newest vertical.
The pilot gives Kalshi a cleaner institutional story than political or sports markets. Hedge funds and pharma investors already price regulatory risk, so the product can slot into existing workflows instead of manufacturing demand from scratch. But low-frequency events like FDA decisions are hard to keep liquid.
Kalshi must attract enough two-sided flow to keep spreads tight, or the pilot will reinforce that prediction-market liquidity clusters around polarized political and sporting events. Thin markets here would waste the institutional credibility this vertical is meant to build. Robust volume would give Kalshi's backers a second hedging use case to cite in regulatory fights, and force Polymarket and ForecastEx to match the expansion or cede the biotech hedging market.